Case Study: Top 10 Pharmaceutical Company achieves 50% faster Phase III diabetes study startup (8 weeks) with Medable

Medable platform speeds diabetes study startup by 50%

Top 10 Pharmaceutical Company engaged Medable to support its Phase III diabetes study in the highly competitive weight‑loss market, aiming to cut average study build timelines from 16–20 weeks down to 8 weeks (a reduction of more than 50%) to accelerate speed to market.

Medable analyzed and streamlined startup processes and implemented its platform for screening, data collection, eCOAs, system integration, configuration, change management, and support. Medable’s solution enabled the study to be built in just 8 weeks from protocol finalization to go‑live, delivered measurable reductions in startup time (>50%), improved site and team efficiency with less back‑and‑forth communication, and created reusable core processes to speed future diabetes trials.